Phase III, randomized, double-blind, multicenter, placebo (P)-controlled trial of rilotumumab (R) plus epirubicin, cisplatin and capecitabine (ECX) as first-line therapy in patients (pts) with advanced MET-positive (pos) gastric or gastroesophageal junction (G/GEJ) cancer: RILOMET-1 study [abstract]
BPC-157 offers a unique solution in post-cycle therapy (PCT) and beyond: Connective Tissue Repair Steroid use can degrade tendon integrity and create microtears under high load
doi: 10.1016/s0022-510x(02)00069-2 22 BjornevikK.CorteseM.HealyB
Peptide therapy in Wyandotte, Michigan, extends beyond just weight loss
More research is needed to better understand the link between obesity and ADHD and the underlying mechanisms
The line to watch is prescription vs